Zydus Bets Big on Affordable GLP-1 Therapy With New Semaglutide Brands in India

ପାଣିପାଗ

ବର୍ଷା ଋତୁରେ କୁହୁଡ଼ି! ଘନ କୁହୁଡ଼ିରେ ଢାଙ୍କିହେଲା ବଣାଇ, ଆଶ୍ଚର୍ଯ୍ୟ...

September 05, 2026

ଦେଶ

ଅଟଳ ଆବାସୀୟ ବିଦ୍ୟାଳୟ: ଉତ୍ତରପ୍ରଦେଶର ମାଗଣା ଆବାସିକ ଶିକ୍ଷା ଯୋଜନା...

September 07, 2026

ବିସ୍ଫୋରଣ ପରେ ପୁଣେରେ ବିଦ୍ୟୁତ ବିପର୍ଯ୍ୟୟ, ୩.୧ ଲକ୍ଷ ଉପଭୋକ୍ତା...

September 07, 2026

ଦିଲ୍ଲୀ PG ଟ୍ରାଜେଡି ଦିନ ପଡ଼ୋଶୀ କୋଠା ପାଇଁ ଡିମୋଲିସନ୍...

September 07, 2026

ଦିଲ୍ଲୀ PG ହଷ୍ଟେଲ ଭୁଶୁଡ଼ିବା ଘଟଣା: ଭଗ୍ନାବଶେଷ ତଳୁ ଛାତ୍ରଙ୍କ...

September 07, 2026

Zydus Bets Big on Affordable GLP-1 Therapy With New Semaglutide Brands in India

Zydus Lifesciences plans to launch its generic semaglutide injection in India on the day the patent expires, offering a more affordable GLP-1 therapy option for diabetes and obesity patients. The drug will be marketed under three brands with a reusable single-pen device to reduce costs and improve convenience.

Published by Somesh | February 26, 2026

Ahmedabad-basedZydus Lifesciences Limitedis set to make a major move in the IndianGLP-1 therapymarket with the launch of its genericsemaglutide injectionimmediately after the drug’s patent expires in late March 2026 — a strategy that could significantly expand access to advanced diabetes and obesity treatment. Semaglutide, aGLP-1 receptor agonist, is widely prescribed globally to improve blood sugar control and support weight loss in patients with Type 2 diabetes and chronic obesity.

Zydus will roll out the therapy under three brand names —SEMAGLYN™, MASHEMA™ and ALTERME™ —in a15 mg/3 mlstrength and has developed an innovativeadjustable reusable single-pen delivery device. This device allows patients to select different dose strengths using a single pen, avoiding the need to buy multiple single-use pens during dose titration. The company holdsexclusive rightsto this novel delivery system in India, which is expected to lower overall treatment costs and improve patient adherence — crucial for chronic, long-term therapy.

The approval from theDrug Controller General of India (DCGI)to manufacture and market semaglutide formulations reflects the regulator’s support for increasing local access to high-impact therapies. As semaglutide’s patent expires, Zydus’ early launch positions it to compete strongly with existing global GLP-1 therapies that have been priced at a premium and seen limited accessibility for many patients in India. Analysts expect broader competition as domestic players gear up for generics, which could potentially lead to price reductions and wider adoption of GLP-1 therapies nationwide.